Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-FPPRGD2
- Development stage
- Phase 2
- Lead developer
- Stanford University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
**18F-FPPRGD2** is a radiopharmaceutical agent consisting of a pegylated dimeric arginine-glycine-aspartic acid (RGD) peptide labeled with the radioisotope fluorine-18 via a 2-fluoropropionyl group. It is designed for positron emission tomography (PET) imaging and specifically targets integrin αvβ3, which plays a key role in angiogenesis and tumor cell adhesion to the extracellular matrix. The compound demonstrates high binding affinity for integrin αvβ3, making it useful for non-invasive imaging of tumors that overexpress this receptor, such as brain, breast, lung, and renal cancers. Its primary clinical application has been in monitoring response to antiangiogenic therapies and early assessment of treatment efficacy in oncology patients[1][4][5][7]. The drug was initially developed by Stanford University[2].
- Other names
- fluorine 18 fpprgd2fluorine18 fpprgd2fluorine-18 fpprgd2peg3-e{c(rgdyk)}2
02
Targets
αVβ3 (Integrin αVβ3)αVβ6 (Integrin αVβ6)
Beyond the preview
Go deeper on 18F-FPPRGD2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-FPPRGD2.